Molecular alterations between the primary breast cancer and the subsequent locoregional/metastatic tumor

Oncologist

Volumn 17, Issue 2, 2012, Pages 172-178

  Macfarlane, Robyn ^a   Seal, Melanie ^a   Speers, Caroline ^a   Woods, Ryan ^a   Masoudi, Hamad ^b   Aparicio, Samuel ^c   Chia, Stephen K ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

Biomarkers; Biopsy; Breast cancer; Metastatic; Molecular phenotype

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RELAPSE; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 84930485134     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0127     Document Type: Article

References (26)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
2. Chia SK, Speers CH, D'yachkova Y et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-979.
3. Hull DF 3rd, Clark GM, Osborne CK et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983;43:413-416.
4. Gross GE, Clark GM, Chamness GC et al. Multiple progesterone receptor assays in human breast cancer. Cancer Res 1984;44:836-840.
5. Simmons C, Miller N, Geddie W et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009;20:1499-1504.
6. Amir E, Ooi WS, Simmons C et al. Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies. Clin Oncol (R Coll Radiol) 2008;20:763-768.
7. Zidan J, Dashkovsky I, Stayerman C et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005;93:552-556.
8. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005;103:1763-7169.
9. Pectasides D, Gaglia A, Arapantoni-Dadioti P et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006;26:647-653.
10. Munzone E, Curigliano G, Rocca A et al. Reverting estrogen-receptornegative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 2006;8:1-4.
11. Liedtke C, Broglio K, Moulder S et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009;20:1953-1958.
12. Yaziji H, Goldstein LC, Barry TS et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 2004;291:1972-1977.
13. Broom RJ, Tang PA, Simmons C et al. Changes in estrogen receptor, progesterone receptor and her-2/neu status with time: Discordance rates between primary and metastatic breast cancer. Anticancer Res 2009;29:1557-1562.
14. Lower EE, Glass EL, Bradley DA et al. Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res Treat 2005;90:65-70.
15. Lipton A, Leitzel K, Ali SM et al. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 2005;104:257-263.
16. Lower EE, Glass E, Blau R et al. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009;113:301-306.
17. Gancberg D, Di Leo A, Cardoso F et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002;13:1036-1043.
18. Cheang MC, Treaba DO, Speers CH et al. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 2006;24:5637-5644.
19. Chia S, Norris B, Speers C et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008;26:5697-5704.
20. Gutierrez MC, Detre S, Johnston S et al. Molecular changes in tamoxifenresistant breast cancer: Relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-2476.
21. Amir E, Clemons M, Freedman OC et al. Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies. J Clin Oncol 2010;28(15s suppl): Abstract 1007.
22. Vance GH, Barry TS, Bloom KJ et al.; College of American Pathologists. Genetic heterogeneity in HER2 testing in breast cancer: Panel summary and guidelines. Arch Pathol Lab Med 2009;133:611-612.
23. Layfield LJ, Saria E, Mooney EE et al. Tissue heterogeneity of immunohistochemically detected estrogen receptor. implications for image analysis quantification. Am J Clin Pathol 1998;110:758-764.
24. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809-813.
25. Wu JM, Fackler MJ, Halushka MK et al. Heterogeneity of breast cancer metastases: Comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008;14:1938-1946.
26. Mobbs BG, Fish EB, Pritchard KI et al. Estrogen and progesterone receptor content of primary and secondary breast carcinoma: Influence of time and treatment. Eur J Cancer Clin Oncol 1987;23:819-826.